Wang Ke-Yi, Wang Hu-Cheng, Jin Xin-Yao, Zhang Ming-Yan, Li Nan, Pang Wen-Tai, Wang Hui, Zhang Jun-Hua
Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 300193, China.
Zhongguo Zhong Yao Za Zhi. 2021 May;46(9):2317-2324. doi: 10.19540/j.cnki.cjcmm.20201230.502.
To systemically evaluate the efficacy and safety of Gingko Ketone Ester Dropping Pills in treating angina pectoris and co-ronary heart disease. CNKI, Wanfang, SinoMed, PubMed, Cochrane Library and EMbase databases were retrieved on computer, and the randomized clinical trial(RCT) on Gingko Ketone Ester Dropping Pills in treating angina pectoris and coronary heart disease, which were published from the database establishment to December 31, 2019, were comprehensively collected. Literature screening, data extraction and quality evaluation were conducted independently by two researchers according to inclusion and exclusion criteria. Literature methodology quality evaluation was conducted with use of the Cochrane Handbook 5.3.0(bias risk assessment tool). Meta-analysis was performed with RevMan 5.3.0 software. A total of 10 RCTs were included. The results of the Meta-analysis showed that as compared with conventional Western medicine alone, the application of Gingko Ketone Ester Dropping Pills combined with conventional Western medicine treatment further improved the total effective rate and electrocardiogram effect(RR=1.43,95%CI[1.20,1.71],P<0.000 1). There were statistically significant differences in the number of angina attacks, the duration of angina and the amount of nitroglycerin used. In terms of safety indicators, four studies reported adverse reactions in the experimental group, including facial flu-shing, tachycardia, dizziness, dyspnea, nausea and other symptoms. Based on the existing findings, in the treatment of angina pectoris and coronary heart disease, Gingko Ketone Ester Dropping Pills combined with conventional Western medicine can improve the clinical total effective rate, electrocardiogram effect, number of angina attacks, duration of angina and the amount of nitroglycerin used. However, in the included studies, due to some methodological quality problems which would impact the reliability of literature results more high-quality randomized controlled trials are still needed for further verification.
为系统评价银杏酮酯滴丸治疗心绞痛及冠心病的有效性和安全性。通过计算机检索中国知网、万方、维普、PubMed、Cochrane图书馆和EMbase数据库,全面收集从各数据库建库至2019年12月31日发表的关于银杏酮酯滴丸治疗心绞痛及冠心病的随机临床试验(RCT)。由两名研究人员根据纳入和排除标准独立进行文献筛选、数据提取和质量评价。采用Cochrane手册5.3.0(偏倚风险评估工具)进行文献方法学质量评价。使用RevMan 5.3.0软件进行Meta分析。共纳入10项RCT。Meta分析结果显示,与单纯使用传统西药相比,银杏酮酯滴丸联合传统西药治疗可进一步提高总有效率和心电图疗效(RR=1.43,95%CI[1.20,1.71],P<0.000 1)。在心绞痛发作次数、心绞痛持续时间和硝酸甘油用量方面存在统计学显著差异。在安全性指标方面,4项研究报告了试验组的不良反应,包括面部潮红、心动过速、头晕、呼吸困难、恶心等症状。基于现有研究结果,在心绞痛及冠心病治疗中,银杏酮酯滴丸联合传统西药可提高临床总有效率、心电图疗效、减少心绞痛发作次数、缩短心绞痛持续时间及减少硝酸甘油用量。然而,在所纳入的研究中,由于一些方法学质量问题可能会影响文献结果的可靠性,仍需要更多高质量的随机对照试验进行进一步验证。